Sesen Bio trial marred by misconduct — report; Bristol Myers picks up development of AI outfit's immunology drug
Sesen Bio said that it was not expecting a CRL from the FDA for its bladder cancer candidate Vicineum. But the rejected filing included thousands …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
